Illumina Inc. announced on April 15, 2025, a collaboration with Tempus AI, Inc. to accelerate the clinical adoption of next-generation sequencing (NGS) tests through novel evidence generation. This partnership aims to combine Illumina's leading AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms.
The collaboration is designed to accelerate clinical adoption of molecular testing for patients, with a vision to make molecular profiling a standard of care across all major categories of disease, including cardiology, neurology, and immunology, not just cancer. This expands on a long-standing relationship between the two companies.
By leveraging Tempus's multimodal data, the initiative will generate new insights supporting the clinical value of sequencing, which will be used to build evidence packages needed to standardize comprehensive genomic profiling and other molecular testing across a wider range of diseases. This strategic move positions Illumina to unlock broader applications for its genomic solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.